A state of relative resistance against the transplantation of isografts of leukemias induced by the Rauscher virus (RV) was developed in HALB/*' an(l CDFi mice by pretreatment with X-irradiated tumor cells. In mice pretreated with cells from 1 tumor, significant cross-protection was obtained for all other RV-induced tumors tested and for some tumors induced by Moloney virus, but not for leukemia LI 210. Although marginal resistance was observed on a few occasions, the inoculation of infectious RV was not an efficient method of inducing trans plantation resistance in BALB/c and CDFi mice. In CDFi mice resistance to grafts of RV-induced tumors was accompanied by resistance to challenge with RV and the presence of circulating RV neutralizing antibodies.
Introduction
Tumors induced by most of the known murine leukemogenic viruses have been reported to have components which are antigenic for syngeneic mice. One general feature of this antigenicity which has been detected by a variety of technics is that all or most of the tumors induced by a single virus seem to possess the same or antigenically related components.
The development of transplantation resistance and circulating antibody demonstrable by either cytotoxicity or immunofluorescence, or both, have teen used to study these relationships with tumors induced by Graffi (12, 13) , Gross (1, 9, 17) , Moloney (6, 8, 15) , Rauscher (5, 11) and Friend (10, 18) viruses. In the current study, data are presented on the development of trans plantation resistance to tumors induced by the Rauscher virus (RV) in mice highly susceptible to the oncogenic potential of RV.
Materials and Methods
MICE.BALB/c and (BALB/c x DBA/2) FI (CD) male mice, 8-12 weeks old, were obtained from the production colonies of the NIH.
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Received for publication November 8, 1965 ; revised February 28, 19(i(i. presented in Table 1 . With the exception of the L1210 sublim- (19) , the tumors were established from primary lymphatic neoplasms of animals that had been inoculated with either Moloney or Rauscher virus when less than 72 hr old. All the tumor stock are maintained by serial transplantation at weekly or bi-weekly intervals.
TRANSPLANTATION. For purposes of quantitating transplanta tion resistance, counted numbers of tumor cells were injected s.c. in the right inguinal region. Usually 3-5 serial dilutions of tumor cells were used with each mouse receiving the appropriate cell concentration in 0.1 ml. All of the transplants grew as local tumors at the site of inoculation and frequently metastasized to other regions. The median survival time of animals inoculated with the minimum cell concentration required to cause 100% death with tumor varied between 20-30 days. Spontaneous regression of the tumors in syngenic mice have not been observed.
IMMUNIZATION. Unless indicated, mice were given 2 injections i.p. of X-irradiated (6000-10,000 r) tumor cells 2 weeks apart. In individual experiments, the numbers of irradiated cells injected ranged from 2 to 7 X 10'/mouse. The challenge with viable tumor cells usually was given 2 weeks after the last immunizing injection.
VIRUS.The virus (14) was obtained from Dr. F. J. Rauscher. Four stocks, designated P-237, P-327, P-387, and P-641, were used. They were all 10<;0extracts of infected BALB/c splenic material. The titers expressed as IDM/ml of the individual preparations were: P-237, IO4-4;P-327, IO5; P-387, IO6-2; and P-641, IO6-8. All virus dilutions were made in phosphate-buffered saline (pH 7.2).
X-IRRADIATION. Tumor cells were irradiated with 2 X-ray tubes placed opposite each other, operated at 200 kvp and 15 ma. Filtration was 0.25 mm Cu and 0.55 mm Al. The target distance was 25 cm and the dose rate was 520 r/min. SKIN GRAFTING. Technic used was that of Billingham and Medawar (3) . Circular disks of skin (9-10 mm in diameter) were cut from the dorsal region of donor and placed on a prepared bed on the lateral aspect of the thorax of recipients. Bandages were removed on the 9th day and the grafts were inspected at regular intervals.
Results
Although many of the transplantation experiments were clone in CDFi mice to provide some flexibility in the use of the available virus-induced tumors, transplantation resistance with RVinduced leukemias was demonstrable in wholly syngeneic sys- however, the parent tumor has been maintained by transplan tation at weekly intervals for several years. tems. The data from a typical experiment with MCDV-12 in BALB/c mice are presented in Table 2 .
In several experiments, groups of CDFi mice immunize to MCDV-12 were challenged with a number of histocompatible neoplasms. Summary data are presented in Table 3 . Significant transplantation resistance was obtained for the 4 RV-induced tumors and for 1 (MCAS-10) of the 2 MV-induced tumors by pretreatment of CDFi mice with X-irradiated MCDV-12 cells. LSTRA and L1210 grew equally well in both control and MCDV-12 immunized animals.
The results of 2 transplantation experiments in which irra diated RCL-1 cells were used to immunize BALB/c (top portion) and CDFi (bottom portion) are shown in Table 4 . In both experi ments, marked inhibition of tumor growth was observed with the RV-induced tumors and, to a lesser extent, with the MV-induced LSTRA. No transplantation resistance for the MV-induced MCAS-10 was seen in CDFi mice pretreated with RCL-1 cells.
Some additional data on cross-protection are presented in Table 5 . The growth of 2 MV-induced tumors was not inhibited in animals pretreated with MCDV-12 cells, although in other experiments these tumors were shown to contain the MV-induced transplantation antigens.
The possibility that the cross-protection observed in CDFi animals was a result of FI anti-parent effects is unlikely. CDFi animals pretreated with a concentration of X-irradiated BALB/c spleen cells approximately equivalent to the concentration of X-irradiated MCDV-12 required for immunization failed to protect the animals to subsequent inoculation with viable MCDV-12 cells (Chart 1). In addition, the results of BALB/c skin grafting and tumor transplantation in CDFi mice pre treated with X-irradiated MCDV-12 cells (Table 6) show that, although pretreatment conferred resistance against tumor challenge, it did not influence the survival of BALB/c skin grafts. An additional injection of X-rayed MCDV-12 cells (5.44 X IO7 cells/mouse) given at 73 days after skin grafting, was without effect. The skin grafts did not show any signs of incompatibility (i.e., loss of hair or shrinkage) when observed for more than 150 days.
Although animals immunized with X-irradiated RV-induced tumor cells did not develop the splenomegalic response usually associated with RV infection, small amounts of infectious RV were detectable in the various tumor lines either by extraction (F. J. Rauscher, personal communication) or by inoculation of X-irradiated cell suspensions into newborn BALB/c mice. Thus, animals immunized with X-irradiated tumor cells are concomitantly infected with low concentrations of RV.
Several attempts were made to determine if infectious virus per se would elicit transplantation resistance in BALB/c or CDFi mice, particularly since in studies (6) with the Moloney virus in these strains of mice, transplantation resistance was produced regularly by X-irradiated tumor cells, but only sporadi cally by infectious virus.
In 1 experiment, groups of adult BALB/c mice inoculated i.p. with 1CT2dilution of RV Stock P-237, were challenged at either 2 or 4 weeks postvirus inoculation with 1 of several dilutions of MCDV-12 cells (Table 7) . As an indication of the infectivity of the virus preparation, 2 weeks after virus inoculation the spleens of the infected mice were slightly but consistently enlarged, and AUGUST 1966 
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CHART!. Mice immunized with X-irradiated (10,000 r) MCDV-12 received 6.9 X 10' and 7.2 X IO7 cells i.p. at 2-week intervals. Groups receiving X-irradiated (10,000 r) BALB/c spleen were given 1.3 X 10" and 6.6 X IO7cells at the same intervals. Mice in all groups received viable MCDV-12 cells s.c. in the right inguinal region 2 weeks after the last pretreatment. Â« Inoculum varied from 3.3 X IO3 to 9 X IO4 cells/mouse. 6 Day of last reading = 150 days after grafting. weeks prior to tumor challenge, and all groups designated to receive a certain level of tumor were inoculated with cells from the same suspension. At the time of tumor challenge, 4 mice from each of the infected groups were sacrificed and the spleen weights recorded. The degree of splenomegaly ranged from an average weight of 1.9 gm in those infected 10 weeks prior to tumor challenge to an average of 0.27 gm for those animals infected 1 week prior to tumor challenge. The average spleen weight of uninfected control mice was 0.15 gm.
The results of another attempt to demonstrate transplantation resistance with infectious RV is shown in Table 8 6 For the 4-week set the x* = 6.37 and P < 0.025. c MST, median survival time (days).
as MCDV-10 cells/mouse was increased approximately 3-fold over that of the controls.
Since transplantation resistance was observed consistently when animals were immunized with X-irradiated tumor cells, this type of system was used to check for cross-protection to an inoculation of infectious RV. CDFi mice immunized with X-irra diated MCDV-12 cells were challenged with RV and, at bi-weekly AUGUST 1966 intervals, groups of 7 animals were sacrificed for spleen weight assay. In a separate group of immunized mice challenged with 2.4 X IO4MCDV-12 cells, only 1 of 10 (1/10) mice developed a tumor. In contrast, all the control mice (10/10) developed tumors. The spleen weight of the RV-infected control animals increased progressively to an average of approximately 1.5 gm at 10 weeks (Chart 2). The average spleen weight of RV-infected immunized mice did not increase progressively, but remained only slightly greater than the average spleen weights of the normal and uninfeeted immunized mice during the entire experi- ment, indicating a strong and persistent inhibition of the early splenomegalic phase of the Rauscher disease.
The plasma collected from animals sacrificed for spleen weight assay in the above experiment (Chart 2) was bioassayed for infectious RV in young BALB/c mice, using the splenomegalic response of the recipients as the indicator of virus activity. The plasma from each group was pooled, diluted in buffered saline (pH 7.2), and each dilution was injected into 5 recipients which were sacrificed for spleen weight assay 28 days later. The results from an assay of the groups sacrificed 6 weeks after infection with RV (Chart 2) are shown in Chart 3. RV was not detectable in the plasma from the immunized animals. Similar assays at 8 and 10 weeks after infection with RV (Chart 2) failed to detect cir culating infectious virus.
The sera of CDFi mice immunized with X-irradiated MCDV-12 cells were tested for their capacity to neutralize RV. Ten-fold dilutions of RV, stock P-641 were mixed with equal volumes either of undiluted pooled immune sera or pooled normal sera, and the mixtures were kept at room temperature for 1 hr with occasional shaking. A group of 5 BALB/c mice were inocu lated i.p. with the serum-virus mixtures and sacrificed 4 weeks later for spleen weight assay. The results (Chart 4) showed that serum from mice pretreated with MCDV-12 neutralized a significant portion of the early splenomegalic response associated with RV infection.
Discussion
The results show that resistance can be developed against the transplantation of RV-induced tumors in BALB/c and CDF (1, 6, 8, 9, 13) , is compromised to a large extent by differences in the strains of mice in which the tumors were induced and the resistance developed. In our experience, RV-and MV-induced (6) RCL-2, a BALB/c tumor induced with RV which had been passaged twice in the rat, was indistinguishable with respect to transplantation resistance from tumors induced with RV of mouse origin. Recently, Hartley et al. (7) have shown that sera CHART 4. Neutralization of RV splenomegalic response. Serum was collected 2 weeks after the last immunization from mice which had received 7.4 X 10' and 0.1 X 1C7irradiated (8000 r) MCDV-12 cells 2 weeks apart. Each group of recipients contained five G-weekold BALB/c male mice, each of which was inoculated i.p. with 0.2 ml of the appropriate mixture. from rats bearing a transplantable RV-induced leukemia would fix complement with extracts from both rat and mouse tumors induced by RV.
Reproducible levels of transplantation resistance to RVinduced tumors were not obtained in BALB/c and CDFi mice by infection with RV. On a few occasions in an extensive series of experiments, marginal resistance was observed to isografts of RV-induced tumors, in contrast to the regular appearance of resistance following pretreatment with inactivated tumor cells. This apparent difference in the immunizing capacity of infectious virus vs. inactivated tumor cells need not necessarily be taken as support for the existence of transplantation antigens on the tumor cells distinct from those of the virus. The ratio of virus antigens to infectious virus might be rather high in tumor cells as compared to infectious virus preparations, and in strains of mice as susceptible as BALB/c and CDFi are to the RV, im munizing concentrations of virus antigen may be achieved with infectious RV only in the presence of a severe viremia and thus be ineffective.
Transplantation resistance produced by pretreatment with X-irradiated cells was accompanied by resistance to challenge with infectious RV and the presence of circulating antibodies capable of neutralizing RV similar to what had been reported by Fink and Rauscher (5) using a virus vaccine. The resistance to RV occurred in animals pretreated with cells from MCDV-12, a poor source of infectious vims, suggesting that the immune response was evoked primarily by the cells rather than by virus shedding from the cells. Barski and Youn (2) found that cells from long term spleen-thymus monolayers chronically infected with RV immunized BALB/c mice against challenge with infectious RV. However, none of the data really preclude the existence of tumor-specific cross-protective transplantation antigens induced by RV. If nonvirus-producing transplantable lines of virus-induced leukemias which did not elicit the produc tion of antiviral antibody could be identified, then transplanta tion studies such as has been done with polyoma tumors (16) could provide some data as to whether the presence of virus antigen is a necessary prerequisite for the demonstration of transplantation resistance.
In some but not all instances, significant cross-resistance for MV-induced tumors was observed in animals pretreated with RV-induced tumors. Whether the differences observed are due to qualitative or quantitative differences is not known. Old et al. (11) , based on serologie studies, have postulated the existence of related cellular antigens (FMR) in leukemias induced by Friend, Moloney, and Rauscher viruses. In a different system, Fink (4) found that BALB/c animals actively immunized with formalinized RV vaccine were protected against challenge with Rauscher and Friend virus, but not against challenge with MV. With respect to transplantation resistance, it would seem that the question of cross-resistance should be studied by obtaining a series of tumors in strains such as C57BL/6 where the tumors seem to be highly antigenic.
